Your browser doesn't support javascript.
loading
Non-alcoholic fatty liver disease increases the risk of biochemical recurrence in high-grade metastatic prostate cancer patients.
Zhang, Hongyi; Yang, Wenbo; Zhang, Bin; Wu, Jiahui; Zhang, Wei; Wang, Zhenlong; Cui, Jie.
Afiliación
  • Zhang H; Department of Urology, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China.
  • Yang W; Department of Oncology, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China.
  • Zhang B; Department of Oncology, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China.
  • Wu J; Department of Oncology, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China.
  • Zhang W; Department of Urology, The Second Affiliated Hospital, Air Forth Medical University, Xi'an, Shaanxi, China.
  • Wang Z; Department of Urology, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • Cui J; Department of General Practice, The First Affiliated Hospital, Xi'an Medical University, Xi'an, Shaanxi, China.
Asia Pac J Clin Oncol ; 20(6): 707-713, 2024 Dec.
Article en En | MEDLINE | ID: mdl-38970310
ABSTRACT

INTRODUCTION:

Non-alcoholic fatty liver disease (NAFLD) has been reported to be helpful to identify high-risk individuals of developing prostate cancer. Our aim is to investigate the relationship between NAFLD and biochemical recurrence in metastatic prostate cancer patients.

METHODS:

We retrospectively investigated 602 patients with metastatic prostate cancer receiving the androgen deprivation therapy. Liver fat was estimated with liver-to-spleen ratio by computed tomography (CT) scans. The relationship between NAFLD and biochemical recurrence was investigated with Cox models. The model for biochemical recurrence was adjusted for multiple variables.

RESULTS:

NAFLD was significantly associated with biochemical recurrence in patients with Gleason score ≥4+3 when adjusting for each of body mass index (hazards ratio [HR] = 1.38; 95% confidence interval [CI] = 1.08-1.77; p = 0.01), visceral adipose tissue (HR = 1.36; 95% CI = 1.07-1.74; p = 0.01), hypertension (HR = 1.41; 95% CI = 1.10-1.80; p = 0.01), and diabetes mellitus (HR = 1.42; 95% CI = 1.11-1.82; p = 0.01), using age and prostate-specific antigen level as potential confounder. The 2-year biochemical recurrence rate in the Gleason score ≥4+3 patients with and without NAFLD was 84.0% (100/119) and 72.2% (130/180), respectively (p = 0.018). The median biochemical recurrence free survival of the Gleason score ≥4+3 patients with and without NAFLD were 17 and 21 months, respectively (p = 0.005).

CONCLUSIONS:

NAFLD is an independent risk factor for biochemical recurrence in patients with high-grade metastatic prostate cancer. If validated in prospective studies, future research should test whether treatment of NAFLD can lead to better prognosis.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Enfermedad del Hígado Graso no Alcohólico / Recurrencia Local de Neoplasia Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Asia Pac J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Enfermedad del Hígado Graso no Alcohólico / Recurrencia Local de Neoplasia Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Asia Pac J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Australia